SANTA CLARA, Calif.--(BUSINESS WIRE)--April 26, 2006--OptiMedica® Corp., a leading developer of ophthalmic therapeutic devices, today announced that it has raised $13.8 million in capital through a Series A and B financing co-led by Kleiner Perkins Caufield & Byers and Alloy Ventures.
Brook Byers, Partner with Kleiner Perkins Caufield & Byers and Chairman of the Board of OptiMedica, commented “There is tremendous opportunity in ophthalmology driven by changes in demography and by diabetes prevalence occurring in epidemic proportions. In OptiMedica we see a management team that has a successful track record in developing breakthrough medical products for all types of ophthalmic innovation needs.”
“OptiMedica is committed to evolving the standards of care in ophthalmology,” said Dr. David Mordaunt, CEO of OptiMedica. “This financing allows us to roll-out technologies to support our mission, while we continue to build our world-class organization centered around our customers -- the physician and ultimately the patient.” Dr. Mordaunt added.
About Kleiner Perkins Caufield & Byers (KPCB)
Since its founding in 1972, KPCB has backed entrepreneurs in 450 ventures, including AOL, Align, Amazon.com, Citrix, Compaq Computer, Electronic Arts, Genentech, Genomic Health, Genprobe, Google, Hybritech, IDEC Pharmaceuticals, Intuit, Juniper Networks, Netscape, Ligand Pharmaceuticals, Lotus, Nuvasive, Sun Microsystems, Symantec, Verisign and Xilinx. KPCB portfolio companies employ more than 250,000 people. More than 150 of the firm’s portfolio companies have gone public. Many other ventures have achieved success through mergers and acquisitions. For more information on KPCB, please visit www.kpcb.com.
About Alloy Ventures
Alloy Ventures was founded in 1996 by partners of Asset Management Company to expand its institutional investor relationships and build on its partners’ rich history of early-stage venture capital investments. With experience spanning several economic cycles, the partners of Alloy Ventures have helped start and cultivate more than 200 successful companies in the fields of information technology and life sciences. For more information, go to www.alloyventures.com.
About OptiMedica
OptiMedica Corp. develops and markets medical devices that treat ophthalmic disorders such as diabetic retinopathy, age-related macular degeneration, retinal vascular occlusive disease and retinal tears and detachments. OptiMedica holds the exclusive license to the PASCAL® (PAttern SCAn Laser) method of photocoagulation and its associated technologies, which are FDA approved to treat a variety of retinal conditions. OptiMedica was founded 2004 in Santa Clara, Calif. and is funded by Kleiner, Perkins, Caufield & Byers and Alloy Ventures. For more information, please visit www.optimedica.com
Contact: OptiMedica Dr. David Mordaunt, 408-850-8600 pr@optimedica.com or Coactive PR Carmen Caricchio, 415-621-6626 optimedica@coactivepr.com
Source: OptiMedica Corp.
